1[1]Ludwig J,Viggiano RT,McGill DB.Nonalcoholic steatohepatitis:mayo clinic experience with a hitherto unnamed disease[J].Mayo Clinic Proc,1980,55:342-348.
2[3]Marchesini G,Brizi M,Bianchi G,et al.Meformin in non-alcoholic steatohepatitis[J].The Lancet,2001,358:893.
3[4]Uygun A,Kadayifei A,Isik At,et al.Mefformin in the treatment of pa-tients with non-alcoholic steatohepatitis[J].Aliment Pharmacol Ther,2004,19:537-544.
4[5]Duseja A,Murtidharau R,Bhansali A,et al.Assessment of insulin resis-tance and effect of metformin in nonalcoholic steatoh epatitis a prelimi-nary repert[J].Indian J Gastmenteml,2004,23:12.
5[6]Neuschwander-Tetri BA,Brunt EM,Wehmeier KR,et al.Improved non-alcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone[J].Hepatology,2003,38:1008-1017.
6[7]Kawaguchi K,Sakaida I,suchiya M,et al.Pioglitazone prevents hepatic steatosis,fibrosis,and enzyme-altered lesions in rat liver cirrhosis in-duced by a choline-deficient L-amino acid-defined diet[J].Biochem Biophys Res Commun,2004,315(l):187-195.
7[8]Rao MS,Papredddy K,Musunmi S,et al.Prevention/reversal of choline deficiency-induced steatohepatitis by a pemxisome proliferator-activat-ed receptor alpha ligands in rats[J].In Vivo,2002,16:145-152.
8[9]lp E,Farrell G,Hall Pet al.Administration of the potent PPAR alpha agonist,Wy-14,643,reverses nultritional fibrosis and steatohepatitis in mice[J].Hepatology,2004,39(5):1286-1296.
9[10]Laurin J,Lindor KD,Crippin JS,et al.Ursodeoxycholic acid or cloff-brate in the treatment on non-alcoholic-induced steatohepatitis:a pilot study[J].Hepatology,1996,23:1464-1467.
10[11]Keith D,Lindor Kris V,Kowdiey E,et al.Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis:results of a randamized trial[J].Hepatology,2004,39:770-778.
